Amneal Pharmaceuticals (AMRX) Other financing activities (2017 - 2026)
Amneal Pharmaceuticals (AMRX) posted quarterly Other financing activities of $2.0 million for Q1 2026, up 2772.46% year-over-year from $69000.0 in Q1 2025, and up 102.71% quarter-over-quarter from -$73.0 million in Q4 2025.
Amneal Pharmaceuticals (AMRX) Other financing activities (2017 - 2026) Analysis & Trends
Amneal Pharmaceuticals' Other financing activities history runs 10 years deep, the most recent figure standing at $2.0 million for Q1 2026.
- In Q1 2026, Other financing activities rose 2772.46% year-over-year to $2.0 million; the TTM figure through Mar 2026 stood at $3.9 million (up 224.1% YoY), while the FY2025 annual figure was $2.0 million, up 69.84% from the prior year.
- Other financing activities for Q1 2026 stood at $2.0 million, up from -$73.0 million in the prior quarter.
- The five-year high for Other financing activities was $73.2 million in Q3 2025, with the low at -$73.0 million in Q4 2025.
- The 5-year median for Other financing activities is $139500.0 (2022), against an average of $443500.0.
- Peak annual rise in Other financing activities reached 7200.9% in 2025, while the deepest fall reached 48452.98% in 2025.
- Amneal Pharmaceuticals' Other financing activities stood at $423000.0 in 2022, then slumped by 89.83% to $43000.0 in 2023, then jumped by 251.16% to $151000.0 in 2024, then tumbled by 48452.98% to -$73.0 million in 2025, then surged by 102.71% to $2.0 million in 2026.
- Business Quant data shows AMRX's Other financing activities at $2.0 million in Q1 2026, -$73.0 million in Q4 2025, and $73.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.34 Bn | 43.37 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.80 Bn | 40.14 Bn | 2.15 Bn |
| 3 | Zoetis | 32.38 Bn | 30.70 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.62 Bn | 22.82 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn |
| 6 | Viatris | 18.94 Bn | 18.06 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.61 Bn | 15.22 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.01 Bn | 11.48 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | Amneal Pharmaceuticals | 5.78 Bn | 5.66 Bn | 334.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.98 Mn |
| Mar 31, 2026 | 1.98 Mn |
| Dec 31, 2025 | -73.01 Mn |
| Dec 31, 2025 | -73.01 Mn |
| Sep 30, 2025 | 73.23 Mn |
| Sep 30, 2025 | 73.23 Mn |
| Jun 30, 2025 | 1.68 Mn |
| Jun 30, 2025 | 1.68 Mn |
| Mar 31, 2025 | 69,000.00 |
| Mar 31, 2025 | 69,000.00 |
| Dec 31, 2024 | 151,000.00 |
| Dec 31, 2024 | 151,000.00 |
| Sep 30, 2024 | 1.00 Mn |
| Sep 30, 2024 | 1.00 Mn |
| Jun 30, 2024 | -28,000.00 |
| Jun 30, 2024 | -28,000.00 |
| Mar 31, 2024 | 28,000.00 |
| Mar 31, 2024 | 28,000.00 |
| Dec 31, 2023 | 43,000.00 |
| Dec 31, 2023 | 43,000.00 |